{
    "relation": [
        [
            "",
            "2000 mg Ofatumumab + DR",
            "2000 mg Ofatumumab + BFR",
            "2000 mg Ofatumumab + Other"
        ],
        [
            "Description",
            "Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as DR, defined as participants who were enrolled in the study and were refractory to both fludarabine and alemtuzumab.",
            "Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as BFR, defined as participants who were enrolled in the study and were refractory to fludarabine with bulky lymphadenopathy.",
            "Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as \"other,\"defined as participants who were enrolled in the study but did not meet criteria for DR or BFR."
        ]
    ],
    "pageTitle": "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00349349?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987552.57/warc/CC-MAIN-20150728002307-00186-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 860571898,
    "recordOffset": 860555957,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: ofatumumab Intervention: Leukaemia, Lymphocytic, Chronic Condition: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Single\u00a0Group\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: October 20, 2011 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 2000 mg Ofatumumab + DR \u00a0 \u00a0 2000 mg Ofatumumab + BFR \u00a0 \u00a0 2000 mg Ofatumumab + Other \u00a0 STARTED \u00a0 \u00a0 95 \u00a0 \u00a0 112 \u00a0 \u00a0 16 \u00a0 COMPLETED \u00a0 \u00a0 42 \u00a0 \u00a0 50 \u00a0 \u00a0 10 \u00a0 NOT COMPLETED \u00a0 \u00a0 53 \u00a0 \u00a0 62 \u00a0 \u00a0 6 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 6 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Withdrawal by Subject \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}